Larimar Therapeutics Completes Expanded Offering, Raising $100 Million at $5.00 Per Share

Larimar Therapeutics, Inc., a development-stage biotechnology company focused on rare disease treatments, successfully concluded its underwritten public offering of 20 million shares at $5.00 per share. The financing initiative generated gross proceeds of approximately $100 million, marking a significant capital infusion for the clinical-stage firm.

The offering was completed with the support of two prominent financial institutions—J.P. Morgan and Guggenheim Securities—who served as co-lead underwriters. Additionally, the underwriting syndicate retained a 30-day option to acquire up to 3 million supplementary shares at the same offering price, minus standard underwriting fees and commissions.

Capital Deployment and Product Development Focus

Larimar intends to channel the net capital toward advancing Nomlabofusp, its lead therapeutic candidate targeting Friedreich’s ataxia, a rare neurodegenerative disorder. Beyond product development, the company plans to allocate funds for operational infrastructure, research initiatives, and eventual commercialization efforts required to bring the treatment to market.

The anticipated closing date for the offering was set for approximately February 27, 2026, with the full transaction now expected to have concluded or be in its final stages.

Market Performance and Investor Response

In the immediate aftermath of the pricing announcement, Larimar’s stock experienced downward pressure, declining 10.92% and trading at $5.30 following the news. This reaction reflects typical market dynamics surrounding equity dilution from new share issuance. Over the trailing twelve-month period, the stock has oscillated between $1.61 and $6.42, demonstrating substantial volatility characteristic of clinical-stage biotech equities.

Prior to the offering announcement, LRMR closed trading at $5.95, reflecting a 61.25% gain from earlier levels, suggesting significant prior market momentum before the pricing event. The company’s ability to execute an upsized offering reflects investor interest in its therapeutic pipeline and rare disease focus.